Here is Matt Lowdon‘s weekly deals update, covering news from medtech and biotech. Congratulations to all involved.
🔔 Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625m offering to fund its pipeline of obesity therapies.
🔔Newly formed medical device manufacturing business Quvara Medical has secured a seven-figure funding package from HSBC UK to acquire a major medical technology production facility in Swindon.
🔔Chinese clinical-stage biotech Oricell Therapeutics announced the cumulative closing of a pre-initial public offering (IPO) financing round in excess of $110m.
🔔Belgian biopharma UCB has agreed to acquire clinical-stage biotech Neurona Therapeutics for up to US$1.15bn, betting on a one-off cell therapy that aims to structurally repair the brains of people with drug-resistant epilepsy.
🔔A newly launched Finnish deep-tech company has cracked the code for single-molecule protein detection. VTT-originated Proteins.1 has launched with €4.7m in pre-seed funding.
🔔The British Business Bank has made its largest funding commitment to date, investing £100m in Apposite Capital Healthcare Growth I.
🔔Clean Food Group has secured £4.5m from a group of investors led by Clean Growth Fund and New Agrarian, together with £700,000 in non-dilutive funding from Innovate UK.
🔔STORM Therapeutics Limited has closed a $56m series C financing as the British biotech kicks off a phase 2 sarcoma trial of its RNA-modifying enzyme inhibitor.
🔔Aligos Therapeutics has secured a $25m cash infusion in return for selling the China rights to its phase 2-stage chronic hepatitis B virus (HBV) treatment to hepatology biopharma Amoytop Biotech.
🔔The Spanish government has announced a goal to raise a $200m venture capital fund as part of a biotech initiative focused on Boston.
🔔Beeline Medicines flew out of stealth today with its stores already filled by an investment team led by Bain Capital, with five autoimmune programs, with $300m series A funding.
🔔Kazia Therapeutics Limited is paying $1.4m upfront to secure a platform for generating epigenetic drugs from an Australian research institute.
🔔Eli Lilly and Company makes preclinical ADC specialist CrossBridge Bio its latest acquisition in vague $300M deal
🔔Harbinger Health raises $100M for new suite of blood-based cancer detection tests